Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America.

Details

Language :

English

ISSN :

00916749

Volume :

137

Database :

Supplemental Index

Journal :

Journal of Allergy & Clinical Immunology

Publication Type :

Academic Journal

Accession number :

112742689

Full Text :

https://doi.org/10.1016/j.jaci.2015.12.856